|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CytImmune Sciences, Inc. With a core focus in oncology, CytImmune will leverage its proprietary pegylated colloidal gold tumor-targeting nanotechnology to develop a new pipeline of multifunctional, next generation therapeutics with faster development timelines, more efficient regulatory approvals, new commercialization value, and greater patient benefit from a wide array of available anti-cancer agents. 9640 Medical Center Drive
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||